Alleviation of colonic inflammation by Lypd8 in a mouse model of inflammatory bowel disease

Int Immunol. 2021 Jun 18;33(7):359-372. doi: 10.1093/intimm/dxab012.

Abstract

Dysfunction of the intestinal mucosal barrier causes inflammatory bowel diseases (IBDs). Indeed, mucosal barrier impairment in the gut of IBD patients results from decreased expression of barrier molecules. Ly6/Plaur domain containing 8 (Lypd8) segregates microbiota from the colonic epithelial layer. In this study, we found that Lypd8-/- mice, in which flagellated bacteria invaded the mucosal surface of the colon, developed spontaneous colitis when dysbiosis was induced by a high-fat diet (HFD). On the basis of this finding, we assessed whether the application of human LYPD8 (hLYPD8) protein exhibiting the glycan-dependent inhibition of bacterial motility is effective in a colitis model. Oral and anal treatments with hLYPD8 protein ameliorate dextran sulfate sodium-induced colitis and HFD-induced colitis in Lypd8-/- mice. These results indicate a therapeutic potential of hLYPD8 protein supplementation for IBD.

Keywords: Lypd8; high-fat diet; inflammatory bowel diseases; mucosal barrier.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Colitis / chemically induced
  • Colitis / metabolism
  • Colon / metabolism*
  • Dextran Sulfate / pharmacology
  • Diet, High-Fat
  • Disease Models, Animal
  • Dysbiosis / chemically induced
  • Dysbiosis / metabolism
  • Female
  • GPI-Linked Proteins / metabolism*
  • Gastrointestinal Microbiome / physiology
  • Humans
  • Inflammation / chemically induced
  • Inflammation / metabolism*
  • Inflammatory Bowel Diseases / chemically induced
  • Inflammatory Bowel Diseases / metabolism*
  • Intestinal Mucosa / metabolism
  • Mice
  • Mice, Inbred C57BL

Substances

  • GPI-Linked Proteins
  • LYPD8 protein, human
  • Ly6-PLAUR domain containing 8 protein, mouse
  • Dextran Sulfate